Home>Topics>Stocks>Alexion Pharmaceuticals

Alexion Pharmaceuticals ALXN

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. ETF Reports
  6. Headlines
    1. If Achillion's Hep C Nucleotide Isn't Best In Class, The Stock Is Worth Low Single Digits

      Headlines

      Tue, 16 Sep 2014

      By Adam Gefvert, CFA : Achillion Pharmaceuticals (NASDAQ: ACHN ) is a biotech company that focuses on developing treatments for Hepatitis C (HCV). Most of the company's value is riding on the success of its nucleotide, ACH-3422. Research suggests that if trials show that this nucleotide works only

    2. Is Intercept Pharmaceuticals Building The Next Great Specialty Franchise?

      Headlines

      Mon, 15 Sep 2014

      By Stephen Simpson, CFA : As great as Alexion (NASDAQ: ALXN ) has shown itself to be with its orphan drug Soliris for rare kidney ailments, Intercept Pharmaceuticals (NASDAQ: ICPT ) may

    3. Japanese regulators tag asfotase alfa an orphan drug for rare bone disorder

      Headlines

      Mon, 8 Sep 2014

      The Japanese Ministry of Health, Labour and Welfare (MHLW) designates Alexion Pharmaceuticals ' (NASDAQ: ALXN ) asfotase alfa an Orphan Drug for the treatment of patients with hypophosphatasis (HPP), an ultra-rare metabolic disease

    4. NICE recommends Soliris for aHUS

      Headlines

      Thu, 4 Sep 2014

      National Institute for Health and Clinical Excellence (NICE) Evaluation Committee recommends funding Alexion Pharmaceuticals ' (NASDAQ: ALXN ) Soliris ( eculizumab ) for the treatment of atypical hemolytic uremic sydrome (aHUS). The Committee's

    5. UK watchdog backs Alexion's "very expensive" drug

      Headlines

      Wed, 3 Sep 2014

      LONDON, Sept 4 (Reuters) - Britain's healthcare cost watchdog has recommended a drug to treat a rare blood disease from U.S. biotech group Alexion Pharmaceuticals , even though it said the medicine was "very expensive".

    6. With An Iffy Non-Oncology Pipeline, Roche Pays Up For InterMune

      Headlines

      Tue, 26 Aug 2014

      remained a frequent flier whenever an analyst or writer has wanted to write up a story on potential biotech/pharma M&A - Roche has been tied to Alexion (NASDAQ: ALXN ), BioMarin (NASDAQ: BMRN ), and Chugai on the more Complete Story »

    7. Alexion commences Soliris label expansion trial

      Headlines

      Mon, 25 Aug 2014

      Alexion Pharmaceuticals (NASDAQ: ALXN ) initiates dosing in a multinational placebo-controlled clinical trial evaluating the safety and efficacy of Soliris ( eculizumab

    8. Cramer's Mad Money - 12 Stocks That Have Performed Better Than Google (8/21/14)

      Headlines

      Fri, 22 Aug 2014

      NASDAQ: GMCR ), Monster Beverage (NASDAQ: MNST ), Priceline (NASDAQ: PCLN ), Apple (NASDAQ: AAPL ), Alexion (NASDAQ: ALXN ), Regeneron (NASDAQ: REGN ), Celgene (NASDAQ: CELG ), Gilead (NASDAQ: GILD ), Netflix (NASDAQ: NFLX ), Intuitive

    9. Alnylam Pharmaceuticals Has Plenty On Its Plate

      Headlines

      Sat, 9 Aug 2014

      By Stephen Simpson, CFA : Investor sentiment, not to mention cash, has been draining out of the biotech sector since the spring of this year, leading to unimpressive performance for leading RNAi companies Alnylam Pharmaceuticals (NASDAQ: ALNY ) and Isis Pharmaceuticals (NASDAQ: ISIS ). I won't try

    10. From Barron’s, August 11, 2014 (Part 1)

      Commentary

      Sat, 9 Aug 2014

      politicians. But that alone won’t stop inversions and possible future candidates with 45% or more revenues from overseas include ALXN , IPG, JCI, OI, MON . For the week , Dow +0.37% , SP500 +0.33% , Nasdaq Comp +0.42% , Russell 2000 +1.48

    « Prev12345Next »
    Content Partners